Polaryx Therapeutics, Inc. (PLYX)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	n/a
Net Income (ttm)	-8.21M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About PLYX

Polaryx Therapeutics is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, po...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: PLYX
• Website: https://polaryx.com/

Financial Performance

Financial numbers in USD